EUCTR2009-009885-15-IT进行中（未招募）1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer - LAP112620_VITA
GlaxoSmithKline Research & Development Ltd0 个研究点目标入组 105 人开始时间: 2009年9月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Signed informed consent prior to registration. 2. Considered by the investigator to have a life expectancy of ≥12 weeks. 3. Subjects must be female and have histologically-confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. Where the disease is restricted to a solitary lesion, the neoplastic nature of the lesion should be confirmed by cytology or histology. 4. Documented overexpression of ErbB2 by 3+ immunohistochemistry or a positive score by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridisation (CISH) using a local laboratory result on a specimen from the primary tumour or visceral metastatic site. Verification by a central laboratory is not required. 5. Subjects should have progressive disease following prior therapy which may include anthracyclines, taxanes, and trastuzumab. Subjects who have not received prior treatment for MBC must fulfill one or more of the following conditions: 1) Relapse following receipt of trastuzumab-based therapy in the adjuvant setting, 2) Contraindication to receiving trastuzumab or documented medical reason for trastuzumab not being appropriate 3) Unsuitable for taxane-based chemotherapy as determined by the study investigator. 6. All prior chemotherapy, immunotherapy, biologic therapy, or surgery (except for minor surgical procedures) must be discontinued or completed at least 4 weeks prior to first dose of randomized study medication. Hormonal therapy must be discontinued at least 1 week prior to first dose. Prior treatment with trastuzumab is permitted provided that at least 6 weeks has elapsed since the last dose of therapy and all treatment-related adverse events are  Grade 1 at the time of randomization. 7. Females aged ≥18 years with any menopausal status: Non-child-bearing potential Child-bearing potential with a negative serum pregnancy test at screening and agree to use acceptable methods of birth control 8. performance status (PS) of 0 to 1. 9. Subjects must have adequate organ and marrow function as defined in Table 3. 10. Subjects must have a cardiac ejection fraction of at least 50% and within the institutional range of normal. 11. Radiotherapy prior to initiation of study medication is allowed to a limited area (e.g., palliative therapy), if it is not the sole site of disease. 12. Subjects with stable central nervous system (CNS) metastases are permitted 13. Subject must be free of gastrointestinal diseases or any other conditions that impede swallowing, retaining, and absorption of oral medications. 14. Bisphosphonate therapy for bone metastases is allowed; however, treatment must be initiated prior to the first dose of study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects taking medications listed in Section 5.9.2 are not eligible for the study. This includes human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. 2. Therapy with lapatinib, vinorelbine, or capecitabine prior to randomization into this study. 3. Prior therapy with more than one chemotherapeutic regimen for metastatic breast cancer. 4. Concurrent anticancer or concomitant radiotherapy treatment. 5. History of uncontrolled or symptomatic angina; history of arrhythmias requiring medications; clinically significant myocardial infarction <6 months from study entry; uncontrolled or symptomatic congestive heart failure; ejection fraction below the institutional normal limit; or any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient. 6. Have current active hepatic or biliary disease (with exception of patients with Gilbert`s syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment). 7. Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of investigational treatment, or, concurrent treatment with an investigational agent or participation in another clinical trial involving investigational agents. 8. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the agents used in this study or their excipients that in the opinion of the investigator or GSK Medical Monitor contraindicates their participation. 9. Known deficiency for the enzyme dihydropyrimidine dehydrogenase (DPD). 10. Known history of uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 11. Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subjects safety. 12. Pregnant or lactating females at any time during the study (due to the potential teratogenic or abortifacient effects of lapatinib and breastfeeding). 13. Subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication, including; malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, small bowel, or colon. Subjects with inflammatory bowel disease or ulcerative colitis are also excluded. 14. Peripheral neuropathy of Grade 2 or greater. 15. Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment. 16. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
研究者
相似试验
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerBreast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-009885-15-FRGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
不适用
A study to determine the safety and efficacy of Laptinib in combination with Vinorelbine or Capecitabine in Women with ErbB2-Overexpressing Metastatic Breast Cancer.Breast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2009-009885-15-BGGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerBreast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-009885-15-GRGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerEUCTR2009-009885-15-DEGlaxoSmithKline Research & Development Ltd105
未知
2 期
Efficacy and Safety Study of CNTO 2476 in Participants with Visual Acuity Impairment Associated with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)JPRN-jRCT1080223359Janssen Pharmaceutical K.K.60